Lifeboat Foundation

7:01 they talk about Church’s comments of ending aging by 2030. Also this appears to be a part one.

In this video Professor Church talks about his theory of aging and touches on his ideas on the future of aging.

Continue reading “My Theory & The Future Of Aging | Prof George Church Interview Series Episode 1” »

I still don’t get how there seems to be No organized effort anywhere to achieve the ability to 3D print a perfect genetic match of all organs by 2025 — 2030. You would think some government somewhere would want to work round the clock on this.

NIBIB-funded engineers at the University of Buffalo have fine-tuned the use of stereolithography for 3D printing of organ models that contain live cells. The new technique is capable of printing the models 10–50 times faster than the industry standard-;in minutes instead of hours-; a major step in the quest to create 3D-printed replacement organs.

Conventional 3D printing involves the meticulous addition of material to the 3D model with a small needle that produces fine detail but is extremely slow —taking six or seven hours to print a model of a human part, such as a hand, for instance. The lengthy process causes cellular stress and injury inhibiting the ability to seed the tissues with live, functioning cells.

Continue reading “New technique can print life-like organ models in minutes” »

After doubling its sample size, the largest study of genetic data from autistic people has identified 255 genes associated with the condition, an increase of more than 40 genes since the researchers’ 2019 update; 71 of the genes rise above a stringent statistical bar the team had not previously used. The new analysis also adds data from people with developmental delay or schizophrenia and considers multiple types of mutations.

“It’s a really significant step forward in what we do,” said Kyle Satterstrom, a computational biologist in Mark Daly’s lab at the Broad Institute in Cambridge, Massachusetts. Satterstrom presented the findings virtually on Tuesday at the 2021 International Society for Autism Research annual meeting. (Links to abstracts may work only for registered conference attendees.)

The team’s previous analyses used data from the Autism Sequencing Consortium, which enrolls families through their doctors. The researchers mainly scoured the genetic data to find rare, non-inherited mutations linked to autism.

People who reach a very old age may have their genes to thank. Genetic variants that help to prevent DNA mutations and repair any that do occur have been found in supercentenarians and semi-supercentenarians – people who reach the ages of 110 and 105, respectively.

“DNA repair mechanisms are extremely efficient in these people,” says Claudio Franceschi at the University of Bologna in Italy. “It is one of the most important basic mechanisms for extending lifespan.”

The human cells grew inside all 132 of the embryos after just 24 hours. After ten days, 103 chimeric embryos remained. By day 19, however, only three chimeras were left alive – and they were then terminated.

“This knowledge will allow us to go back now and try to re-engineer these pathways that are successful for allowing appropriate development of human cells in these other animals,” Juan Carlos Izpisua Belmonte, genetics professor at the Salk Institute for Biological Sciences in La Jolla, California and co-author of the study, told NPR.

“We are very, very excited,” he added.

Genetic treatments are difficult to produce without facilities.

Af­ter Kel­li Lug­in­buhl fin­ished her PhD, her ad­vi­sor, Duke bio­engi­neer and Phase­Bio co-founder Ashutosh Chilkoti, sat her down and asked if she want­ed to launch and then run a com­pa­ny. Chilkoti had a once-ob­scure tech­nol­o­gy he and the ven­ture cap­i­tal­ist Joe McMa­hon thought could form the ba­sis of his sec­ond com­pa­ny and fi­nal­ly pay huge div­i­dends. Lug­in­buhl knew the tech from years in his lab and was al­ready look­ing for biotech jobs. It all added up.

Three years, some strate­giz­ing, and 10 or so pitch meet­ings lat­er, the trio is launch­ing Isol­ere Bio, with $7 mil­lion in seed fund­ing led by North­pond Ven­tures and tech­nol­o­gy they be­lieve can al­low gene ther­a­py com­pa­nies to vast­ly in­crease the num­ber of dos­es they can pro­duce. It’s one po­ten­tial so­lu­tion to a slow-boil­ing cri­sis that has be­come in­creas­ing­ly acute, as new com­pa­nies strug­gle to get the ma­te­ri­als they need for tri­als and some com­mon dis­eases re­main the­o­ret­i­cal­ly un­fix­able by gene ther­a­py, be­cause com­pa­nies would nev­er be able to make enough dos­es for that many patients.

Continue reading “Startup sets out to tackle the gene therapy manufacturing crisis” »

After a decade of fighting for regulatory approval and public acceptance, a biotechnology firm has released genetically engineered mosquitoes into the open air in the United States for the first time. The experiment, launched this week in the Florida Keys — over the objections of some local critics — tests a method for suppressing populations of wild Aedes aegypti mosquitoes, which can carry diseases such as Zika, dengue, chikungunya and yellow fever.

Biotech firm Oxitec launches controversial field test of its insects in Florida after years of push-back from residents and regulatory complications.

Unlocking The Potential Of Salt and Drought Tolerant Crops And Seawater Agriculture — Professor Dr. Mark Tester — Center for Desert Agriculture, King Abdullah University of Science and Technology; Co-founder & CSO, Red Sea Farms.

Professor Dr. Mark Tester is Professor, Plant Science, and Associate Director, Center for Desert Agriculture, Biological and Environmental Science and Engineering Division, of King Abdullah University of Science and Technology (KAUST) in Saudi Arabia.

Continue reading “Professor Dr. Mark Tester — Center for Desert Agriculture — KAUST — Red Sea Farms — Saudi Arabia” »

In a study at The University of Alabama, aging fruit flies died faster than younger flies from a viral infection because of different genetic responses, lowering the older flies’ tolerance to the infection.

The findings published recently in G3: Genes, Genomes, Genetics add to the understanding of innate immunity, the first line of defense against infections, which is not fully understood in humans, and prove the fruit fly, Drosophila, is a good candidate for aging immunity studies that could lead to advancements in treating viral infections in older humans.

“We are living in times where there is a substantial increase in aging populations, and we know there is a decline of immune function in humans as we age,” said Dr. Stanislava Chtarbanova, UA assistant professor of biological sciences whose lab led the study. “This is the first study to use the fly for investigating age-dependent, anti-viral responses. Our lab can leverage this genetic model to study the molecular mechanisms underlying aging immunity.”